InvestSMART

CurveBeam AI Limited (ASX:CVB)

ALERT: Price-sensitive ASX Announcement for CVB
Current share price for CVB : $0.022 -0.038 (-63.33%)+
Announcement
Release
30 Apr 2026 8:14AM
Price at Release
$0.060
Full Release
download
Summary
During the Q3 FY26 Quarterly Results Investor Webinar, CurveBeam AI Limited reported receiving purchase orders for five devices, primarily the HiRise™ model. The company is on track for HiRise™ sales in China following the NMPA clearance, with significant collaboration underway with WEGO Orthopaedics. Progress is also noted in developing the total hip arthroplasty protocol for robotic surgery systems and receiving feedback on the FDA 510(k) application for the BMD module. Financially, the company reported A$1.4m in receipts for Q3 FY26, a 7% decrease from the previous year, but carried forward A$5.4m into Q4. The cash position remains strong, with strategic partnerships in Greater China aiming for a 10-year exclusive licensing agreement.
Key Points
  • CurveBeam AI received POs for five devices in Q3 FY26.
  • HiRise™ sales in China are on track post-NMPA clearance.
  • Collaborations with WEGO Orthopaedics are advancing.
  • FDA feedback received for BMD module, targeting H2 CY26 clearance.
  • Receipts for Q3 FY26 were A$1.4m, a decrease from FY25.
  • Strong cash position with A$5.4m carried into Q4 FY26.
  • Strategic partnership in Greater China with a 10-year exclusive agreement.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.